Cellectis S.A. (CLLS)
NASDAQ: CLLS · IEX Real-Time Price · USD
2.030
-0.130 (-6.02%)
At close: Jul 19, 2024, 4:00 PM
2.190
+0.160 (7.88%)
Pre-market: Jul 22, 2024, 6:47 AM EDT
Cellectis Revenue
Cellectis had revenue of $12.13M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $6.50M with 82.58% year-over-year growth. In the year 2023, Cellectis had annual revenue of $9.19M.
Revenue (ttm)
$12.13M
Revenue Growth
-52.39%
P/S Ratio
11.41
Revenue / Employee
$54,896
Employees
221
Market Cap
138.44M USD
Revenue Chart
* The company reports in EUR currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 9.19M | -16.53M | -64.26% |
Dec 31, 2022 | 25.73M | -12.87M | -33.35% |
Dec 31, 2021 | 38.60M | -20.97M | -35.20% |
Dec 31, 2020 | 59.56M | 36.57M | 159.09% |
Dec 31, 2019 | 22.99M | 1.56M | 7.27% |
Dec 31, 2018 | 21.43M | -12.28M | -36.43% |
Dec 31, 2017 | 33.72M | -22.73M | -40.27% |
Dec 31, 2016 | 56.44M | -6.12M | -9.78% |
Dec 31, 2015 | 62.57M | 31.43M | 100.95% |
Dec 31, 2014 | 31.14M | 16.16M | 107.90% |
Dec 31, 2013 | 14.98M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCLLS News
- 23 days ago - Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024 - GlobeNewsWire
- 4 weeks ago - Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing - GlobeNewsWire
- 5 weeks ago - Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications - GlobeNewsWire
- 6 weeks ago - Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia - GlobeNewsWire
- 7 weeks ago - Cellectis' Annual Shareholders General Meeting to be Held on June 28, 2024 - GlobeNewsWire
- 7 weeks ago - Cellectis Reports Financial Results for First Quarter 2024 - GlobeNewsWire
- 7 weeks ago - Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024 - GlobeNewsWire
- 2 months ago - Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca - GlobeNewsWire